Published in

SSRN Electronic Journal, 2022

DOI: 10.2139/ssrn.4172086

Links

Tools

Export citation

Search in Google Scholar

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Journal article published in 2022 by Marius Trøseid, Jr Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzić, Fulvia Mazzaferri, Jesús Rodríguez-Baño, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Püntmann, Thale Patrick-Brown and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO